866-997-4948(US-Canada Toll Free)

Non-Small Cell Lung Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Aug 2013

Category :

Cancer

No. of Pages : 447 Pages


Global Markets Directs, \'Non-Small Cell Lung Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Non-Small Cell Lung Cancer Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Non-Small Cell Lung Cancer 16
Non-Small Cell Lung Cancer Therapeutics under Development by Companies 18
Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Non-Small Cell Lung Cancer Therapeutics - Products under Development by Companies 43
Non-Small Cell Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 65
Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 75
Bristol-Myers Squibb Company 75
Boehringer Ingelheim GmbH 76
F. Hoffmann-La Roche Ltd. 77
Biogen Idec Inc. 78
Shionogi & Co., Ltd. 79
Amgen Inc. 80
Sanofi-Aventis 81
AstraZeneca PLC 82
Eli Lilly and Company 83
GlaxoSmithKline plc 85
Genentech, Inc. 86
Nektar Therapeutics 87
Inovio Biomedical Corporation 88
MedImmune LLC 89
Isis Pharmaceuticals, Inc. 90
Daiichi Sankyo Company, Ltd 91
Merck & Co., Inc. 92
Infinity Pharmaceuticals, Inc. 93
Takeda Pharmaceutical Company Limited 94
YM BioSciences Inc. 95
Celltrion, Inc. 96
Prolexys Pharmaceuticals, Inc. 97
Millennium Pharmaceuticals, Inc. 98
Novartis AG 99
Astellas Pharma Inc. 100
Biocon Limited 101
Chong Kun Dang Pharmaceutical 102
Eisai Co., Ltd. 103
ImmunoGen, Inc. 104
Laboratoires Pierre Fabre SA 105
Ono Pharmaceutical Co., Ltd. 106
Pfizer Inc. 107
SuperGen, Inc. 108
Taiho Pharmaceutical Co., Ltd. 109
Teva Pharmaceutical Industries Limited 110
Cell Therapeutics, Inc. 111
Exelixis, Inc. 112
Aduro BioTech 113
Cyclacel Pharmaceuticals Inc. 114
Alfacell Corporation 115
Celgene Corporation 116
Bayer AG 117
Geron Corporation 118
Aeolus Pharmaceuticals, Inc. 119
Merck KGaA 120
EntreMed, Inc. 121
Hana Biosciences, Inc. 122
Celldex Therapeutics, Inc. 123
AEterna Zentaris Inc. 124
ImmunoCellular Therapeutics, Ltd. 125
Idera Pharmaceuticals, Inc. 126
Ariad Pharmaceuticals, Inc. 127
Lorus Therapeutics Inc 128
Benitec Ltd. 129
MethylGene Inc 130
Northwest Biotherapeutics, Inc. 131
Novogen Limited 132
Cleveland BioLabs, Inc. 133
Oncothyreon Inc 134
Compugen Ltd. 135
OXiGENE, Inc. 136
Peregrine Pharmaceuticals, Inc. 137
Critical Outcome Technologies Inc. 138
Curis, Inc. 139
Telik, Inc. 140
CytRx Corporation 141
Regeneron Pharmaceuticals, Inc. 142
Oncogenex Pharmaceuticals, Inc. 143
MOLOGEN AG 144
Quest PharmaTech Inc. 145
Threshold Pharmaceuticals, Inc. 146
Synta Pharmaceuticals Corp. 147
Natco Pharma Limited 148
Simcere Pharmaceutical Group 149
Sun Pharma Advanced Research Company 150
Morphotek, Inc. 151
Spectrum Pharmaceuticals, Inc. 152
Chipscreen Biosciences Ltd 153
CIMAB S.A. 154
Bionucleon Srl 155
GANYMED Pharmaceuticals AG 156
Ora Bio Ltd. 157
Philogen S.p.A. 158
NovaRx Corporation 159
Nerviano Medical Sciences S.r.l. 160
Cadila Pharmaceuticals Ltd. 161
Hutchison MediPharma Limited 162
immatics biotechnologies GmbH 163
Vaxon Biotech 164
CureVac GmbH 165
BioNumerik Pharmaceuticals, Inc. 166
Altor BioScience Corporation 167
Alder Biopharmaceuticals Inc. 168
Ascenta Therapeutics, Inc. 169
Cerulean Pharma, Inc. 170
Heat Biologics, Inc. 171
MacroGenics, Inc. 172
OncoMed Pharmaceuticals, Inc. 173
DanDrit Biotech A/S 174
Azaya Therapeutics, Inc. 175
CanBas Co., Ltd. 176
Merrimack Pharmaceuticals, Inc. 177
Neotropix, Inc. 178
Mersana Therapeutics, Inc. 179
Axelar AB 180
Proacta, Inc. 181
Advenchen Laboratories, LLC 182
MolMed S.p.A. 183
Innogene Kalbiotech Pte Ltd. 184
Syndax Pharmaceuticals, Inc. 185
KangLaiTe USA 186
Mirna Therapeutics, Inc. 187
Globeimmune, Inc. 188
Tragara Pharmaceuticals, Inc. 189
Taiwan Liposome Company 190
Cellceutix Corporation 191
PharmaMar, S.A. 192
CG Therapeutics, Inc. 193
Quintessence Biosciences, Inc. 194
Sirnaomics, Inc. 195
Biothera 196
Nereus Pharmaceuticals, Inc. 197
AVEO Pharmaceuticals, Inc. 198
Medisyn Technologies, Inc. 199
Pique Therapeutics 200
Clovis Oncology, Inc. 201
Toko Pharmaceutical Industries Co., Ltd. 202
Cancer Therapeutics CRC Pty Ltd 203
Medical Enzymes AG 204
KAEL-GemVax 205
iCeutica, Inc. 206
Mebiopharm Co., Ltd. 207
Vichem Chemie Research Ltd. 208
Agennix AG 209
Regulon Inc. 210
CellAct Pharma GmbH 211
Oncozyme Pharma Inc. 212
Optimum Therapeutics, LLC 213
Non-Small Cell Lung Cancer - Therapeutics Assessment 214
Assessment by Monotherapy Products 214
Assessment by Combination Products 215
Assessment by Route of Administration 216
Assessment by Molecule Type 218
Drug Profiles 221
eribulin mesylate - Drug Profile 221
motesanib diphosphate - Drug Profile 223
necitumumab - Drug Profile 226
sorafenib tosylate - Drug Profile 228
cetuximab - Drug Profile 232
vandetanib - Drug Profile 238
emepepimut-S - Drug Profile 240
onartuzumab - Drug Profile 243
dacomitinib - Drug Profile 245
crizotinib - Drug Profile 247
dimesna - Drug Profile 250
paclitaxel - Drug Profile 252
KD-019 - Drug Profile 254
iniparib - Drug Profile 256
ramucirumab - Drug Profile 258
GV-1001 - Drug Profile 262
canfosfamide hydrochloride - Drug Profile 264
Racotumomab - Drug Profile 268
YN-968D1 - Drug Profile 269
nintedanib - Drug Profile 272
tirapazamine - Drug Profile 274
Docetaxel + Vinorelbine - Drug Profile 275
Docetaxel + Infliximab - Drug Profile 276
pemetrexed disodium + [cisplatin] - Drug Profile 277
ipilimumab + [carboplatin] + [paclitaxel] - Drug Profile 279
cetuximab + [carboplatin] + [paclitaxel] + Radiation Therapy - Drug Profile 281
Docetaxel + Cisplatin - Drug Profile 283
belagenpumatucel-L - Drug Profile 285
cisplatin + [gemcitabine] - Drug Profile 287
Hycamtin + Radiation Therapy - Drug Profile 289
custirsen sodium + [docetaxel] - Drug Profile 290
[carboplatin] + [motesanib] + [paclitaxel] - Drug Profile 292
afatinib - Drug Profile 294
afatinib - Drug Profile 296
vandetanib + [pemetrexed disodium] - Drug Profile 298
dimesna + [cisplatin] + [docetaxel] - Drug Profile 300
cetuximab + [docetaxel] + [pemetrexed disodium] - Drug Profile 302
cetuximab + [docetaxel] + [pemetrexed] - Drug Profile 304
rebimastat + [carboplatin] + [paclitaxel] - Drug Profile 306
GSK-2132231-A - Drug Profile 308
GSK-1572932A - Drug Profile 310
necitumumab + [cisplatin] + [pemetrexed disodium] - Drug Profile 312
necitumumab + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 314
S-1 + Cisplatin - Drug Profile 316
Docetaxel + Cisplatin - Drug Profile 318
Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 320
ardeparin sodium - Drug Profile 321
nivolumab - Drug Profile 322
pravastatin sodium + [cisplatin] + [docetaxel] - Drug Profile 324
Docetaxel + Cisplatin - Drug Profile 325
Navelbine + Carboplatin - Drug Profile 326
uracil + tegafur - Drug Profile 327
tegafur + urasil - Drug Profile 328
Docetaxel + S-1 - Drug Profile 329
BV-NSCLC-001 - Drug Profile 330
cisplatin - Drug Profile 331
bevacizumab - Drug Profile 333
erlotinib hydrochloride - Drug Profile 337
erlotinib hydrochloride - Drug Profile 340
celecoxib + [carboplatin] + [gemcitabine hydrochloride] + [pemetrexed disodium] - Drug Profile 343
cediranib maleate + [carboplatin] + [paclitaxel] - Drug Profile 344
cetuximab + [carboplatin] + [paclitaxel] - Drug Profile 346
Docetaxel + Carboplatin - Drug Profile 348
(tegafur + gimeracil + oteracil potassium) - Drug Profile 349
talactoferrin alfa + [carboplatin] + [paclitaxel] - Drug Profile 352
Recombinant Human Endostatin + [cisplatin] + [vinorelbine tartrate] - Drug Profile 354
cetuximab + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile 356
bevacizumab biosimilar - Drug Profile 358
Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates 359
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products 400
Non-Small Cell Lung Cancer Therapeutics - Dormant Products 407
Non-Small Cell Lung Cancer - Product Development Milestones 434
Featured News & Press Releases 434

Appendix 441
Methodology 441
Coverage 441
Secondary Research 441
Primary Research 441
Expert Panel Validation 441
Contact Us 442
Disclaimer 442

List of Table


Number of Products Under Development for Non-Small Cell Lung Cancer, H2 2013 21
Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2013 22
Number of Products under Development by Companies, H2 2013 24
Number of Products under Development by Companies, H2 2013 (Contd..1) 25
Number of Products under Development by Companies, H2 2013 (Contd..2) 26
Number of Products under Development by Companies, H2 2013 (Contd..3) 27
Number of Products under Development by Companies, H2 2013 (Contd..4) 28
Number of Products under Development by Companies, H2 2013 (Contd..5) 29
Number of Products under Development by Companies, H2 2013 (Contd..6) 30
Number of Products under Development by Companies, H2 2013 (Contd..7) 31
Number of Products under Development by Companies, H2 2013 (Contd..8) 32
Number of Products under Development by Companies, H2 2013 (Contd..9) 33
Number of Products under Development by Companies, H2 2013 (Contd..10) 34
Number of Products under Investigation by Universities/Institutes, H2 2013 36
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 38
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..3) 39
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..4) 40
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..5) 41
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..6) 42
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..7) 43
Comparative Analysis by Late Stage Development, H2 2013 44
Comparative Analysis by Mid Clinical Stage Development, H2 2013 45
Comparative Analysis by Early Clinical Stage Development, H2 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 47
Products under Development by Companies, H2 2013 48
Products under Development by Companies, H2 2013 (Contd..1) 49
Products under Development by Companies, H2 2013 (Contd..2) 50
Products under Development by Companies, H2 2013 (Contd..3) 51
Products under Development by Companies, H2 2013 (Contd..4) 52
Products under Development by Companies, H2 2013 (Contd..5) 53
Products under Development by Companies, H2 2013 (Contd..6) 54
Products under Development by Companies, H2 2013 (Contd..7) 55
Products under Development by Companies, H2 2013 (Contd..8) 56
Products under Development by Companies, H2 2013 (Contd..9) 57
Products under Development by Companies, H2 2013 (Contd..10) 58
Products under Development by Companies, H2 2013 (Contd..11) 59
Products under Development by Companies, H2 2013 (Contd..12) 60
Products under Development by Companies, H2 2013 (Contd..13) 61
Products under Development by Companies, H2 2013 (Contd..14) 62
Products under Development by Companies, H2 2013 (Contd..15) 63
Products under Development by Companies, H2 2013 (Contd..16) 64
Products under Development by Companies, H2 2013 (Contd..17) 65
Products under Development by Companies, H2 2013 (Contd..18) 66
Products under Development by Companies, H2 2013 (Contd..19) 67
Products under Development by Companies, H2 2013 (Contd..20) 68
Products under Development by Companies, H2 2013 (Contd..21) 69
Products under Investigation by Universities/Institutes, H2 2013 70
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 71
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 72
Products under Investigation by Universities/Institutes, H2 2013 (Contd..3) 73
Products under Investigation by Universities/Institutes, H2 2013 (Contd..4) 74
Products under Investigation by Universities/Institutes, H2 2013 (Contd..5) 75
Products under Investigation by Universities/Institutes, H2 2013 (Contd..6) 76
Products under Investigation by Universities/Institutes, H2 2013 (Contd..7) 77
Products under Investigation by Universities/Institutes, H2 2013 (Contd..8) 78
Products under Investigation by Universities/Institutes, H2 2013 (Contd..9) 79
Bristol-Myers Squibb Company, H2 2013 80
Boehringer Ingelheim GmbH, H2 2013 81
F. Hoffmann-La Roche Ltd., H2 2013 82
Biogen Idec Inc., H2 2013 83
Shionogi & Co., Ltd., H2 2013 84
Amgen Inc., H2 2013 85
Sanofi-Aventis, H2 2013 86
AstraZeneca PLC, H2 2013 87
Eli Lilly and Company, H2 2013 89
GlaxoSmithKline plc, H2 2013 90
Genentech, Inc., H2 2013 91
Nektar Therapeutics, H2 2013 92
Inovio Biomedical Corporation, H2 2013 93
MedImmune LLC, H2 2013 94
Isis Pharmaceuticals, Inc., H2 2013 95
Daiichi Sankyo Company, Ltd, H2 2013 96
Merck & Co., Inc., H2 2013 97
Infinity Pharmaceuticals, Inc., H2 2013 98
Takeda Pharmaceutical Company Limited, H2 2013 99
YM BioSciences Inc., H2 2013 100
Celltrion, Inc., H2 2013 101
Prolexys Pharmaceuticals, Inc., H2 2013 102
Millennium Pharmaceuticals, Inc., H2 2013 103
Novartis AG, H2 2013 104
Astellas Pharma Inc., H2 2013 105
Biocon Limited, H2 2013 106
Chong Kun Dang Pharmaceutical, H2 2013 107
Eisai Co., Ltd., H2 2013 108
ImmunoGen, Inc., H2 2013 109
Laboratoires Pierre Fabre SA, H2 2013 110
Ono Pharmaceutical Co., Ltd., H2 2013 111
Pfizer Inc., H2 2013 112
SuperGen, Inc., H2 2013 113
Taiho Pharmaceutical Co., Ltd., H2 2013 114
Teva Pharmaceutical Industries Limited, H2 2013 115
Cell Therapeutics, Inc., H2 2013 116
Exelixis, Inc., H2 2013 117
Aduro BioTech, H2 2013 118
Cyclacel Pharmaceuticals Inc., H2 2013 119
Alfacell Corporation, H2 2013 120
Celgene Corporation, H2 2013 121
Bayer AG, H2 2013 122
Geron Corporation, H2 2013 123
Aeolus Pharmaceuticals, Inc., H2 2013 124
Merck KGaA, H2 2013 125
EntreMed, Inc., H2 2013 126
Hana Biosciences, Inc., H2 2013 127
Celldex Therapeutics, Inc., H2 2013 128
AEterna Zentaris Inc., H2 2013 129
ImmunoCellular Therapeutics, Ltd., H2 2013 130
Idera Pharmaceuticals, Inc., H2 2013 131
Ariad Pharmaceuticals, Inc., H2 2013 132
Lorus Therapeutics Inc, H2 2013 133
Benitec Ltd., H2 2013 134
MethylGene Inc, H2 2013 135
Northwest Biotherapeutics, Inc., H2 2013 136
Novogen Limited, H2 2013 137
Cleveland BioLabs, Inc., H2 2013 138
Oncothyreon Inc, H2 2013 139
Compugen Ltd., H2 2013 140
OXiGENE, Inc., H2 2013 141
Peregrine Pharmaceuticals, Inc., H2 2013 142
Critical Outcome Technologies Inc., H2 2013 143
Curis, Inc., H2 2013 144
Telik, Inc., H2 2013 145
CytRx Corporation, H2 2013 146
Regeneron Pharmaceuticals, Inc., H2 2013 147
Oncogenex Pharmaceuticals, Inc., H2 2013 148
MOLOGEN AG, H2 2013 149
Quest PharmaTech Inc., H2 2013 150
Threshold Pharmaceuticals, Inc., H2 2013 151
Synta Pharmaceuticals Corp., H2 2013 152
Natco Pharma Limited, H2 2013 153
Simcere Pharmaceutical Group, H2 2013 154
Sun Pharma Advanced Research Company, H2 2013 155
Morphotek, Inc., H2 2013 156
Spectrum Pharmaceuticals, Inc., H2 2013 157
Chipscreen Biosciences Ltd, H2 2013 158
CIMAB S.A., H2 2013 159
Bionucleon Srl, H2 2013 160
GANYMED Pharmaceuticals AG, H2 2013 161
Ora Bio Ltd., H2 2013 162
Philogen S.p.A., H2 2013 163
NovaRx Corporation, H2 2013 164
Nerviano Medical Sciences S.r.l., H2 2013 165
Cadila Pharmaceuticals Ltd., H2 2013 166
Hutchison MediPharma Limited, H2 2013 167
immatics biotechnologies GmbH, H2 2013 168
Vaxon Biotech, H2 2013 169
CureVac GmbH, H2 2013 170
BioNumerik Pharmaceuticals, Inc., H2 2013 171
Altor BioScience Corporation, H2 2013 172
Alder Biopharmaceuticals Inc., H2 2013 173
Ascenta Therapeutics, Inc., H2 2013 174
Cerulean Pharma, Inc., H2 2013 175
Heat Biologics, Inc., H2 2013 176
MacroGenics, Inc., H2 2013 177
OncoMed Pharmaceuticals, Inc., H2 2013 178
DanDrit Biotech A/S, H2 2013 179
Azaya Therapeutics, Inc., H2 2013 180
CanBas Co., Ltd., H2 2013 181
Merrimack Pharmaceuticals, Inc., H2 2013 182
Neotropix, Inc., H2 2013 183
Mersana Therapeutics, Inc., H2 2013 184
Axelar AB, H2 2013 185
Proacta, Inc., H2 2013 186
Advenchen Laboratories, LLC, H2 2013 187
MolMed S.p.A., H2 2013 188
Innogene Kalbiotech Pte Ltd., H2 2013 189
Syndax Pharmaceuticals, Inc., H2 2013 190
KangLaiTe USA, H2 2013 191
Mirna Therapeutics, Inc., H2 2013 192
Globeimmune, Inc., H2 2013 193
Tragara Pharmaceuticals, Inc., H2 2013 194
Taiwan Liposome Company, H2 2013 195
Cellceutix Corporation, H2 2013 196
PharmaMar, S.A., H2 2013 197
CG Therapeutics, Inc., H2 2013 198
Quintessence Biosciences, Inc., H2 2013 199
Sirnaomics, Inc., H2 2013 200
Biothera, H2 2013 201
Nereus Pharmaceuticals, Inc., H2 2013 202
AVEO Pharmaceuticals, Inc., H2 2013 203
Medisyn Technologies, Inc., H2 2013 204
Pique Therapeutics, H2 2013 205
Clovis Oncology, Inc., H2 2013 206
Toko Pharmaceutical Industries Co., Ltd., H2 2013 207
Cancer Therapeutics CRC Pty Ltd, H2 2013 208
Medical Enzymes AG, H2 2013 209
KAEL-GemVax, H2 2013 210
iCeutica, Inc., H2 2013 211
Mebiopharm Co., Ltd., H2 2013 212
Vichem Chemie Research Ltd., H2 2013 213
Agennix AG, H2 2013 214
Regulon Inc., H2 2013 215
CellAct Pharma GmbH, H2 2013 216
Oncozyme Pharma Inc., H2 2013 217
Optimum Therapeutics, LLC, H2 2013 218
Assessment by Monotherapy Products, H2 2013 219
Assessment by Combination Products, H2 2013 220
Assessment by Stage and Route of Administration, H2 2013 222
Assessment by Stage and Molecule Type, H2 2013 225
Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates 364
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products 405
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..1) 406
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..2) 407
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..3) 408
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..4) 409
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..5) 410
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products (Contd..6) 411
Non-Small Cell Lung Cancer Therapeutics - Dormant Products 412
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..1) 413
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..2) 414
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..3) 415
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..4) 416
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..5) 417
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..6) 418
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..7) 419
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..8) 420
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..9) 421
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..10) 422
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..11) 423
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..12) 424
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..13) 425
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..14) 426
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..15) 427
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..16) 428
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..17) 429
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..18) 430
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..19) 431
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..20) 432
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..21) 433
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..22) 434
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..23) 435
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..24) 436
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..25) 437
Non-Small Cell Lung Cancer Therapeutics - Dormant Products (Contd..26) 438

List of Chart


Number of Products under Development for Non-Small Cell Lung Cancer, H2 2013 21
Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2013 22
Products under Development by Companies, H2 2013 23
Products under Investigation by Universities/Institutes, H2 2013 35
Late Stage Products, H2 2013 44
Mid Clinical Stage Products, H2 2013 45
Early Clinical Stage Products, H2 2013 46
Discovery and Pre-Clinical Stage Products, H2 2013 47
Assessment by Monotherapy Products, H2 2013 219
Assessment by Combination Products, H2 2013 220
Assessment by Route of Administration, H2 2013 221
Assessment by Stage and Route of Administration, H2 2013 222
Assessment by Molecule Type, H2 2013 223
Assessment by Stage and Molecule Type, H2 2013 224

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *